Detalhe da pesquisa
1.
Risk of flare and damage accrual after tapering glucocorticoids in modified serologically active clinically quiescent patients with systemic lupus erythematosus: a multinational observational cohort study.
Ann Rheum Dis
; 2024 Feb 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-38423757
2.
SMART-SLE: serology monitoring and repeat testing in systemic lupus erythematosus-an analysis of anti-double-stranded DNA monitoring.
Rheumatology (Oxford)
; 63(2): 525-533, 2024 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37208196
3.
Comparison of Attainment and Protective Effects of Lupus Low Disease Activity State In Patients With Newly Diagnosed Versus Established Systemic Lupus Erythematosus.
J Rheumatol
; 2024 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38490668
4.
Impact of remission and low disease activity on health-related quality of life in patients with systemic lupus erythematosus.
Rheumatology (Oxford)
; 61(12): 4752-4762, 2022 11 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-35302581
5.
Laboratory investigation results influence Physician's Global Assessment (PGA) of disease activity in SLE.
Ann Rheum Dis
; 79(6): 787-792, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32241797
6.
Lupus Low Disease Activity State (LLDAS) discriminates responders in the BLISS-52 and BLISS-76 phase III trials of belimumab in systemic lupus erythematosus.
Ann Rheum Dis
; 78(5): 629-633, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30679152
7.
Rituximab treatment in primary angiitis of the central nervous system.
Intern Med J
; 48(6): 724-727, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29898271
8.
Response to: 'Phsician's global assessment is often useful in SLE, but not always: the case of clinical remission' by Zen et al.
Ann Rheum Dis
; 81(5): e78, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32434819
9.
Response to: 'Physician global assessment in systemic lupus erythematosus: can we rely on its reliability?' by Chessa et al.
Ann Rheum Dis
; 81(5): e80, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32461205
10.
Correspondence to 'Time to change the primary outcome of lupus trials'.
Ann Rheum Dis
; 80(7): e109, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31420326
11.
Refractory discoid lupus erythematosus responds to rituximab.
Australas J Dermatol
; 62(2): e341-e343, 2021 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-33216961
12.
Response to: 'Achieving lupus low disease activity and remission states under belimumab in refractory systemic lupuserythematosus: time and organ involvement matter' by Sbeih et al.
Ann Rheum Dis
; 79(11): e149, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31285258
13.
Efficacy and safety of treat-to-target strategy studies in rheumatic diseases: A systematic review and meta-analysis.
Semin Arthritis Rheum
; 67: 152465, 2024 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-38796922
14.
Real-world implications of IMACS malignancy screening guidelines for idiopathic inflammatory myopathies: An evaluation of compliance and economic impact at a tertiary referral center.
Int J Rheum Dis
; 27(5): e15198, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38769913
15.
Diagnosing and characterizing inflammatory myopathies at an Australian tertiary public hospital: Resource utilization and direct healthcare costs.
Int J Rheum Dis
; 27(4): e15153, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38661316
16.
Association of systemic lupus erythematosus standard of care immunosuppressants with glucocorticoid use and disease outcomes: a multicentre cohort study.
Adv Rheumatol
; 64(1): 38, 2024 05 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-38720354
17.
Association of sustained lupus low disease activity state with improved outcomes in systemic lupus erythematosus: a multinational prospective cohort study.
Lancet Rheumatol
; 2024 Jun 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-38876129
18.
CSL362 potently and specifically depletes pDCs invitro and ablates SLE-immune complex-induced IFN responses.
iScience
; 26(7): 107173, 2023 Jul 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-37456846
19.
Impact of low disease activity, remission, and complete remission on flares following tapering of corticosteroids and immunosuppressive therapy in patients with systemic lupus erythematous: a multinational cohort study.
Lancet Rheumatol
; 5(10): e584-e593, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-38251484
20.
Association of Modified Systemic Lupus Erythematosus Responder Index Attainment With Long-Term Clinical Outcomes: A Five-Year Prospective Study.
Arthritis Rheumatol
; 75(3): 401-410, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36122172